Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

NCT00226954 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Urologic Neoplasms

Interventions

DRUG: zoledronic acid

Sponsor

Stanford University

Collaborators

[object Object]